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Background: Renal disease is one of the leading causes of morbidity and mortality among people infected with human immuno-
deficiency virus (HIV). However, there are very few published studies about renal insufficiency in HIV-infected persons in Asia, 
especially in South Korea.
Materials and Methods: A cross-sectional study was performed to investigate the prevalence and risk factors of renal insufficien-
cy, defined as <60 mL/min/1.73 m2, in subjects in the Korea HIV/AIDS Cohort Study enrolled from 19 institutions between De-
cember 2006 and July 2013. Data at entry into the cohort were analyzed.
Results: Of 454 enrolled subjects, 24 (5.3%) showed renal insufficiency at entry into the cohort. The mean age of patients in the 
renal insufficiency group was 5.28 years and the majority were male subjects (91.7%). All the patients were receiving antiretrovi-
ral agents, mostly protease inhibitor-based regimens (76.4%), for an average of 19 months. In univariate analysis, older age (P = 
0.002), diabetes mellitus (DM) (P = 0.0002), unknown route of transmission (P = 0.007), and taking indinavir (P = 0.0022) were 
associated with renal insufficiency. In multivariable analysis, older age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.03–
1.12, P = 0.002], DM [OR 3.03, 95% CI 1.17–7.82, P = 0.022], unknown route of transmission [OR 6.15, 95% CI 1.77–21.33, 
P = 0.004], and taking indinavir [OR 3.07, 95% CI 1.17–8.05, P = 0.023] were independent risk factors of renal insufficiency.
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Introduction
As a result of the development of combination antiretroviral 
therapy (ART), human immunodeficiency virus (HIV) infec-
tion is now a chronic disease rather than an acute infectious 
disease. The importance of early diagnosis and care of age-re-
lated non-communicable diseases (NCDs) in HIV-infected pa-
tients has recently been emphasized [1-4]. Although ART has 
significantly decreased the mortality rate from HIV infection, 
the prevalence of major NCDs, including metabolic, cardiovas-
cular, kidney, and bone-related complications, has increased 
owing to increased survival of chronically HIV-infected pa-
tients [5-8] According to a modeling study, the prevalence of 
NCDs in this population is expected to increase from 29% in 
2010 to 84% in 2030 [4]. Renal insufficiency is one of the im-
portant NCDs and is independently associated with morbidity 
and mortality in HIV patients [9-11]. After the first report of 
HIV-associated nephropathy (HIVAN) in 1984 [12], there have 
been several research studies on the association between HIV 
infection and development of renal dysfunction HIV infection 
is not only an independent risk factor for acute kidney injury 
(AKI) [13], but also a potential risk factor of chronic renal in-
sufficiency due to harmful complex mechanisms including di-
rect viral cell injury, chronic inflammation, aging, co-infec-
tions, and use of nephrotoxic drugs [8, 14, 15]. Traditional risk 
factors for renal insufficiency are age, hypertension (HTN), 
and diabetes mellitus (DM) [8, 16]. In HIV patients, additional 
HIV-related factors including low CD4 counts, high viral load, 
hepatitis C virus (HCV) co-infection, and ART (mainly tenofo-
vir, indinavir, and lopinavir/ritonavir) may also be potential 
risk factors [7, 8, 14, 17]. The prevalence of renal insufficiency 
in HIV patients varies among studies owing to differences in 
the studied populations, historic periods, and settings as well 
as the estimated glomerular filtration rate (eGFR) equations 
used to evaluate renal function [8, 18, 19]. Furthermore, there 
are very few published studies about renal insufficiency in 
HIV-infected patients in Asia, especially in South Korea. There-
fore, we investigated the prevalence and risk factors of renal 
insufficiency in HIV-infected patients in South Korea.
Materials and Methods
1. Study design and populations
The Korea HIV/AIDS Cohort Study is a multicenter prospec-
tive cohort study with ongoing enrollment of HIV-infected pa-
tients from 19 hospitals in South Korea. At the time of registra-
tion, the enrolled participants are interviewed by a trained 
clinical researcher and baseline information on clinical and 
epidemiological data is collected using a standardized proto-
col [20]. Information on medical history, physical findings, and 
laboratory findings, including immunological and virological 
status, is collected every 6 months. This was a cross-sectional 
point prevalence study. We performed a case–control study 
with 1,218 HIV-infected patients older than 18 years who were 
enrolled from December 2006 to July 2013. To evaluate the 
prevalence and risk factors of renal insufficiency, we investi-
gated baseline data at the time of registration in the Korea 
HIV/AIDS Cohort Study.
2. Collected data
Infection with HIV was screened using enzyme immunoas-
says and confirmed by western blot analysis. Renal insufficien-
cy was defined as an eGFR <60 mL/min/1.73 m2 at the time of 
registration. Using serum creatinine levels, eGFR was calculat-
ed using the simplified modification of diet in renal disease 
(MDRD) equation [21]. The eGFR results were stratified accord-
ing to the National Kidney Foundation Kidney Disease Out-
come Quality Initiative (NKF-K/DOQI) staging system [22]. All 
of the patients classified in stages 3 through 5 (i.e., with eGFR 
<60 mL/min/1.73 m2) were considered to have renal insuffi-
ciency. Creatinine was measured using isotope dilution mass 
spectrometry traceable calibration. End-stage renal disease 
(ESRD) was defined as eGFR <15 mL/min/1.73 m2 and/or treat-
Conclusion: The prevalence of renal insufficiency in HIV-infected subjects in this study was relatively low, similar to that in other 
countries. Aging, DM, and taking indinavir were significantly associated with decreased glomerular filtration rate. Furthermore, 
unknown route of transmission was an independent risk factor, which was interpreted as a reflection of patient compliance. Further 
studies on the incidence and risk factors of renal insufficiency during HIV infection using follow-up cohort data are necessary.
Key Words: Human immu nodeficiency virus; Renal insufficiency; Prevalence; Risk factors
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ment with renal replacement therapy. The collected data in-
cluded sex, age, body mass index (BMI), time since diagnosis 
with HIV infection, opportunistic infection, co-infection with 
hepatitis B virus (HBV, defined as a positive hepatitis B surface 
antigen test), co-infection with HCV (defined as positive an-
ti-HCV serology), DM (defined as a fasting plasma glucose ≥126 
mg/dL or the use of antidiabetic drugs), HTN (defined as sys-
tolic blood pressure (BP) ≥140 mmHg and/or diastolic BP ≥90 
mmHg and/or use of antihypertensive therapy), cardiovascular 
disease (CVD, defined as a history of any of the following: coro-
nary heart disease, cerebrovascular disease, peripheral arterial 
disease), coronary heart disease (defined as a history of angio-
plasty, coronary artery bypass grafts, myocardial infarction, or 
angina), cerebrovascular disease (history of transient ischemic 
attack, stroke, or carotid endarterectomy), peripheral vascular 
disease (defined as a history of claudication, ischemic limb loss 
and/or ulceration, or a peripheral revascularization procedure), 
route of transmission, CD4 cell count, HIV viral load, ART his-
tory, and serum chemistry at study enrollment. We excluded 
patients who were not Korean or had a lack of sufficient data. In 
cases when eGFR was not known, the absence of a significant 
factor such as HTN, DM, and BMI or an unknown ART history 
were excluded from the analysis.
3. Statistical analysis
Correlations of various factors were compared according to 
renal function status. None of the continuous variables except 
for age followed a normal distribution, and therefore, median 
and interquartile range (IQR, Q1 – Q3) are presented after a 
median two-sample test was used to evaluate significance. 
When the categorical variables expected value are <5, the sig-
nificant difference was confirmed using Fisher’s exact test. Stu-
dent’s t-test was used for the other continuous variables and 
the Chi-square test was used for categorical variables. Regres-
sion analysis was used for the correlation analysis and the final 
model was constructed by using the stepwise selection vari-
ables option in the logistic regression procedure after simple 
logistic regression was performed for the variables with signifi-
cant differences between the groups. The significance level for 
entry into the model was defined as 0.2. The clinically defined 
confounding variable, HTN, was excluded by the selection 
method. As there was an interaction between HTN and ART 
regimens, we presented adjusted odds ratios (aORs) using a 
stratified method. The explanatory power of the regression 
Total Number enrolled
n=1,218
Korean HIV-infected patients
n=884
Patients receiving ART
n=460
454 individuals were
included for analysis
Excluded (n=6) 
* Missing serum creatinine (n=6)
Excluded (n=424) 
* Missing route of transmission (n=22)
* Missing years since HIV infection (n=4)
* Missing current CD4 cell count (n=148)
* Missing current HIV RNA copies (n=39)
* Missing duration of ART (n=211)
Excluded (n=334) 
* Missing age (n=1)
* Not Korean (n=12)
* Missing BMI (n=321)
Figure 1. Exclusion criteria of study population.
HIV, human immunodeficiency virus; RNA, ribonucleic acid; ART, antiretroviral treatment. 
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equation was presented as the adjusted max-rescaled r2 value. 
The cumulative number of subjects with renal insufficiency 
was shown. The statistical significance level was 5% (P value = 
0.05). All statistical analyses were performed using the SAS sta-
tistical program version 9.3 (SAS Institute, Cary, NC, USA).
4. Ethics approval
All participants provided written informed consent and eth-
ics approval was obtained from the Institutional Review Board 
of each participating institute.
Results
Clinical characteristics of patients and risk factors 
associated with renal insufficiency
A total of 1,218 HIV patients were enrolled from December 
2006 to July 2013. Owing to missing data and being non-Kore-
an, 764 patients were excluded from analyses. We analyzed 
data from 454 patients (Fig. 1). Of 454 patients, only 24 showed 
renal insufficiency (eGFR <60 mL/min/1.73 m2), a prevalence 
Table 1. Distribution of the HIV/AIDS cohort of HIV-infected patients based on eGFR categories 
CKD stage, eGFR (MDRD), mL/min/1.73 m2
n (%)
Total M F
Stage 1 (≥90) 271 (59.7) 254 (59.6) 17 (60.7)
Stage 2 (60–89) 159 (35.0) 151 (35.2) 9 (32.1)
Stage 3a (45–59) 18 (4.0) 17 (4.0) 1 (3.6)
Stage 3b (30–44) 4 (0.9) 3 (0.7) 1 (3.6)
Stage 4 (15–29) 1 (0.2) 1 (0.2) 0 (0.0)
Stage 5 (<15) 1 (0.2) 1 (0.2) 0 (0.0)
Total 454 (100.0) 426 (93.8) 28 (6.2)
HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; MDRD, modifi-
cation of diet in renal disease; M, male; F, female. 
Table 2. Distribution of the HIV/AIDS cohort of HIV-infected patients based on age
eGFR 
n (%)
Total <35a 35–44a 45–54a 55–64a 65≤a
Stage 1 271 (59.7) 82 (75.9) 81 (65.8) 72 (52.6) 29 (43.9) 7 (35.0)
Stage 2 159 (35.0) 23 (24.1) 37 (30.1) 56 (40.9) 31 (47.0) 9 (45.0)
Stage 3a 18 (4.0) 0 (0.0) 5 (4.1) 6 (4.4) 5 (7.6) 2 (10.0)
Stage 3b 4 (0.9) 0 (0.0) 0 (0.0) 1 (0.7) 1 (1.5) 2 (10.0)
Stage 4 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
Stage 5 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
Total 454 (100.0) 108 (23.8) 123 (27.1) 137 (30.2) 66 (14.5) 20 (4.4)
aAge.
eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; CKD, chronic kidney disease; MDRD, modification of diet in renal disease; M, 
male; F, female.
Figure 2. Cumulative numbers of renal insufficiency cases in Korean 
HIV-infected patients for each year of the study
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Table 3. Demographic and clinical variables in HIV-infected patients with and without renal insufficiency
Factors
n (%)
P-value
Total
Patients with normal 
kidney function
Patients with renal 
insufficiency
n 454 (100.0) 430 (94.7) 24 (5.3) <0.0001
Demographic factors
　 Age (years)a 43.8 ± 11.8 43.4 ± 11.8 52.8 ± 9.4 0.0002
　 　 <35 108 (23.8) 108 (25.1) 0 (0.0)
0.0007
　 　 35–44 123 (27.1) 118 (27.4) 5 (20.8)
　 　 45–54 137 (30.2) 128 (29.8) 9 (37.5)
　 　 55–64 66 (14.5) 60 (13.9) 6 (25.0)
　 　 ≥65 20 (4.4) 16 (3.7) 4 (16.7)
　 Sex 　 　 　 　 　
　 　 Men 426 (93.8) 404 (94.0) 22 (91.7)
0.653b　 　 Women 28 (6.2) 26 (6.1) 2 (8.3)
　 BMI (kg/m2)a 22.1 ± 2.9 22.1 ± 2.9 22.8 ± 2.9 0.239
　 　 <Q1 (<20.28) 113 (24.9) 109 (25.4) 4 (16.7)
0.176　 　 Q1–Q3 (20.28–23.84) 227 (50.0) 217 (50.5) 10 (41.7)
　 　 ≥Q3 (≥23.84) 114 (25.1) 104 (24.2) 10 (41.7)
Mode of transmission 　 　 　 　
　 Homosexual 218 (48.0) 209 (48.6) 9 (37.5)
0.022b
　 Heterosexual 174 (38.3) 166 (38.6) 8 (33.3)
　 Bisexual 30 (6.6) 29 (6.7) 1 (4.2)
　 Unknown 32 (7.1) 26 (6.1) 6 (25.0)
HIV related factors 　 　 　 　
　 Duration of known HIV infection (months)c 33 (13–69) 33 (13–69) 41 (8–77) 0.830d
　 Opportunistic infection 255 (56.2) 244 (56.7) 11 (45.8) 0.297
　 CD4 count (/mm3)c 405.5 (230–528) 380 (230–528) 400 (190–578) 0.175d
　 HIV RNA (copies/mL)c 39 (19–232) 39 (19–292) 25 (20–75) 0.502d
　 HBV coinfection 28 (6.2) 26 (6.1) 2 (8.3) 0.653b
　 HCV coinfection 5 (1.1) 4 (0.9) 1 (4.2) 0.239b
ART 　 　 　 　
　 ART 454 (100.0) 430 (100.0) 24 (100.0) -
　 PI-based regimen 347 (76.4) 324 (75.2) 23 (100.0) 0.0003
　 Exposure to indinavir 55 (12.1) 47 (10.9) 8 (33.3) 0.004b
　 Exposure to tenofovir 0 (0.0) 0 (0.0) 0 (0.0) -
　 Regimen 　 　 　 　
　 　 PI (except indinavir) 292 (64.3) 276 (64.2) 16 (66.7) 0.804
　 　 PI-based regimen with indinavir 55 (12.1) 47 (10.9) 8 (33.3) 0.004b
　 Duration of ART (months)c 19 (4–47) 19 (4–45) 29 (5–67) 0.635d
Underlying diseases 　 　 　 　
　 Diabetes mellitus 53 (11.7) 44 (10.2) 9 (37.5) 0.0007b
　 Hypertension 103 (22.7) 96 (22.3) 7 (29.2) 0.449
　 Chronic liver disease 37 (8.2) 34 (7.9) 3 (12.5) 0.433b
　 Cardiovascular disease 2 (0.4) 2 (0.5) 0 (0.0) 1.000
　 Rheumatologic disease 1 (0.2) 1 (0.2) 0 (0.0) 1.000
　 Malignancy 12 (2.6) 10 (2.3) 2 (8.3) 0.128b
Renal function 　 　 　 　
　 eGFR (mL/min/1.73 m2)c 102.3 (81.9–108.6) 94.6 (84.2–109.6) 55.2 (46.2–58.2) <0.001d
　 ESRD 1 (0.2) 0 (0.0) 1 (4.2) 1.000
aMean ± standard deviation. 
bFisher's exact test. 
cMedian (interquartile range). 
dMedian two sample test.
HIV, human immunodeficiency virus; BMI, body mass index; RNA, ribo nucleic acid; HBV, hepatitis B virus; HCV, hepatitis C virus; ART, antiretroviral treatment; PI, protease 
inhibitor; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
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of 5.3%. After excluding only the 128 patients with no eGFR 
data, 44 of 1,090 patients showed renal insufficiency (4.04%). 
According to the NKF-K/DOQI staging system, 271 patients 
(59.6%) had stage 1 (eGFR ≥90 mL/min/1.73 m2) and 160 
(35.2%) had stage 2 (eGFR 60~89 mL/min/1.73 m2) kidney dis-
ease (Table 1). There was only one patient with ESRD (0.2%). 
The cumulative number of patients with renal insufficiency in 
Korean HIV-infected patients in our cohort for each year was 
demonstrated (Fig. 2).
We analyzed the distribution HIV-infected patients by eGFR 
and age (Table 2). We found that 23.8% of patients under 35 
years of age did not have renal insufficiency. The mean age of 
patients with renal insufficiency was 52.8 ± 9.4 years, which 
was significantly older than patients with normal renal func-
tion (43.4 ± 11.8 years, P = 0.0002). When the data were ana-
lyzed according to age categories, the results remained signifi-
cant with respect to more renal insufficiency in older patients. 
Sex and BMI were not significantly different in both groups. 
When BMI was categorized as IQR or classified according to 
the World Health Organization criteria, the renal insufficiency 
group tended to be more overweight, but this was not signifi-
cant. Male sex was predominant in both groups (94.0% vs. 
91.7%). Regarding the route of transmission, the proportion of 
homosexual transmission was lower and that of unknown 
route of transmission was significantly higher in the renal in-
sufficiency group than that in the normal renal function group.
In the renal insufficiency group, 37.5% and 29.2% of patients 
had diabetes and HTN, and diabetes was significantly more 
common than in the normal renal function group (10.2% vs. 
37.5%, P = 0.0007). The HBV and HCV co-infection rates were 
also not different between the two groups. The mean CD4 cell 
count was 400 (IQR 190–578) cells/mm3 and mean HIV viral 
load was 25 (IQR 20–75) copies/mL. The mean CD4 cell count 
and HIV viral load in the renal insufficiency group were not 
different from those in the normal renal function group.
All of the patients were receiving ART (100%), the majority 
with a protease inhibitor (PI)-based regimen, for an average du-
ration of 29 (interquartile range [IQR] 5–67) months in the renal 
insufficiency group and 19 (IQR 4–45) months in the normal re-
nal function group (not a statistically significant difference). No 
subjects in either group were taking tenofovir, and the propor-
tion of patients taking indinavir was significantly higher in the 
renal insufficiency group than in the normal renal function 
group [33.3% (8/24) vs. 10.9% (47/430), P = 0.004], respectively. 
There was a significant correlation between use of a PI-based 
regimen and renal insufficiency, but it was not significant except 
for indinavir in a PI-based regimen. Therefore, it was interpreted 
that exposure to indinavir had a significant effect on correlation, 
which was considered in the univariate and multivariable analy-
ses. Other PIs were not significantly correlated with renal insuffi-
Table 4. Risk factors associated with renal insufficiency (<60 mL/min per 1.73 m2) in HIV-infected patients in logistic analysis
Factors Crude OR (95% CI) P-value Adjusted OR (95% CI)a P-value
R2 (%) 6.9
Max-rescaled R2 (%) 20.4
Exposure to indinavir 4.08 (1.66–10.03) 0.0022 3.07 (1.17–8.05) 0.023
Age (years) (vs. <55)
　 55–64 2.53 (0.94–6.84) 0.068 2.78 (0.96–8.09) 0.06
　 ≥65 6.32 (1.87–21.39) 0.003 6.84 (1.71–27.34) 0.007
Route of transmission (vs. heterosexual)
　 Homosexual 0.89 (0.34–2.37) 0.821 1.13 (0.40–3.16) 0.816
　 Bisexual 0.72 (0.09–5.94) 0.757 0.53 (0.06–4.88) 0.576
　 Unknown 4.79 (1.54–14.92) 0.007 6.15 (1.77–21.33) 0.004
BMI (kg/m2) (vs. <Q1 (<20.28)) 
　 Q1–Q3 (20.28–23.84) 1.26 (0.39–4.10) 0.706 -
　 ≥Q3 (≥23.84) 2.62 (0.80–8.62) 0.113 -
DM 　 5.26 (2.18–12.73) 0.0002 3.03 (1.17–7.82) 0.022
HTNb 1.43 (0.58–3.56) 0.438 -
aStepwise selection variables.
bInteraction.
HIV, human immunodeficiency virus; OR, odds ratio; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension.
Kim EJ, et al. • Renal insufficiency in HIV patients www.icjournal.org200
ciency and are not presented separately (Table 3).
In univariate analysis, older age (≥65 years) (P = 0.003), un-
known transmission (P = 0.007), DM (P = 0.0002), and receiv-
ing PI-based ART with indinavir (P = 0.0022) were associated 
with renal insufficiency in HIV-infected patients. However, sex, 
other underlying diseases, baseline CD4 cell count, HIV RNA 
titer, HBV/HCV co-infection, and use of tenofovir were not as-
sociated with renal insufficiency (Table 4). In multivariable 
analysis, older age (≥65 years) [aOR 6.84, 95% confidence in-
terval (CI) 1.71–27.34, P = 0.007], unknown transmission (aOR 
6.42, 95% CI 1.83–22.55, P = 0.004), exposure to indinavir (aOR 
3.52, 95% CI 1.32–9.35, P = 0.012), and DM (aOR 3.60, 95% CI 
1.38–9.36, P = 0.009) were independent risk factors of renal in-
sufficiency in HIV-infected patients (Table 4). In addition, as 
there was an interaction between HTN and ART regimens (in-
teraction P-value = 0.0487), we performed an additional strati-
fied multivariable analysis (Table 5). In patients with HTN, in-
dinavir exposure (aOR 29.80, 95% CI 2.99–297.23, P = 0.004) 
and DM (aOR 8.64, 95% CI 1.12–66.50, P = 0.038) were signifi-
cant risk factors of renal insufficiency. In patients without 
HTN, older age (≥65 years) (aOR 10.20, 95% CI 2.15 – 48.51, P = 
0.004) and unknown route of transmission (aOR 5.92, 95% CI 
1.36 – 25.72, P = 0.018) were significant risk factors. The explan-
atory power of the regression model verified by the adjusted 
max-rescaled R2 value was higher after performing the strati-
fied analysis (Table 5).
Discussion
Our cross-sectional study shows the prevalence and associ-
ated risk factors of renal insufficiency in HIV-infected patients. 
Renal disease is increasingly becoming recognized as a major 
global health problem and is associated with a poor health 
outcome in HIV-infected patients. There is a growing concern 
that HIV significantly contributes to the prevalence of renal in-
sufficiency worldwide [8, 23]. Although the incidence of ESRD 
in HIV-infected individuals has decreased over time, HIV pa-
tients are still more likely than HIV-negative individuals to de-
velop ESRD [24]. The incidence of renal insufficiency is in-
creasing in HIV-infected patients living in Asian countries [25] 
as well as those in Western countries. The overall prevalence of 
chronic renal insufficiency among the general population in 
the United States is 13.1% and the reported prevalence in 
South Korea is 13.7% [26, 27]. As mentioned above, the preva-
lence of HIV-associated renal insufficiency varies geographi-
cally and also depends on the definition of renal insufficiency, 
ranging from 4.7% to 38% globally [19]. In North America and 
Europe, the reported prevalence of renal insufficiency (defined 
as eGFR <60 mL/min/1.73 m2) among HIV-infected patients 
ranges from 4.7% to 9.7% [28, 29]. However, if the renal insuffi-
ciency definition includes reduced eGFR and/or proteinuria, 
the rate increases to 15.5% [30]. Notably, regarding genetic fac-
tors, the prevalence of renal insufficiency in HIV-infected Afri-
can populations seems to be higher, in the range of 3.5–48.5%, 
and related to polymorphisms in the apolipoprotein L1 
(APOL1) gene that is related to a high risk for developing 
HIVAN [17, 31, 32]. In a study in China, 16.8% of HIV-infected 
patients had chronic renal insufficiency (defined as eGFR <60 
mL/min/1.73 m2 and/or proteinuria), but this study reported a 
prevalence of just decreased eGFR (<60 mL/min/1.73 m2) of 
5.6% [25]. In addition, studies in Japan have reported renal in-
Table 5. Stratified multivariable analysis of independent risk factors associated with renal insufficiency in HIV-infected patients
Factors
Adjusted OR (95% CI)a
Without HTN (n = 351) P-value With HTN (n = 103) P-value
R2 (%) 5.8 17.9 　
Max-rescaled R2 (%) 18.0 45.7 　
Exposure to Indinavir 1.48 (0.42–5.14) 0.540 19.80 (2.56–152.97) 0.004
Age (years)
　 55–64 4.40 (1.29–15.02) 0.018 2.01 (0.13–30.30) 0.615
　 ≥65 10.20 (2.15–48.51) 0.004 7.79 (0.34–177.37) 0.198
Route of transmission (vs. heterosexual)
　 Homosexual 0.88 (0.27–2.93) 0.839 1.36 (0.15–12.60) 0.787
　 Bisexual 0.67 (0.07–6.32) 0.728 - -
　 Unknown 5.21 (1.22–22.21) 0.026 8.52 (0.57–127.23) 0.121
DM 　 2.25 (0.68–7.42) 0.185 8.85 (1.22–64.08) 0.031
aStratified interaction variables.
HIV, human immunodeficiency virus; OR, odds ratio; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus.
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sufficiency (defined as eGFR <60 mL/min/1.73 m2) prevalence 
rates from 6.7% to 9.7% [33, 34]. In a Korean chronic kidney 
disease (CKD) cohort study, using just decreased eGFR (<60 
mL/min/1.73 m2) as a criterion, the prevalence was 5.0% [27]. 
Likewise, in our study, the prevalence of renal insufficiency in 
HIV-infected patients was 5.3%, which was similar in the gen-
eral population in Korea and in other studies of HIV-infected 
patients [27, 35]. However, there is a limitation that the defini-
tion of renal insufficiency was defined only as a reduction in 
eGFR (<60 mL/min/1.73 m2). If proteinuria was added to the 
definition as in other studies, the prevalence might have in-
creased [30]. However, just a single eGFR value <60 mL/
min/1.73 m2 was significantly associated with an increased 
mortality and cardiovascular risk [7, 36]. Nevertheless, this 
study is meaningful as the first report to investigate the preva-
lence of renal insufficiency in Korean HIV-infected patients. 
The prevalence of decreased eGFR in Korean HIV-infected 
patients was relatively low compared with that in an African 
HIV population, which may be related to the following rea-
sons. Overall, a quarter of HIV-infected patients are co-infected 
with HCV, and HCV co-infection may cause specific immune 
complex-mediated kidney disease. In this regard, HCV co-in-
fection is associated with a significant increase in the risk of 
HIV-related renal disease [35]. However, in this study, this fac-
tor did not show significance. In Korea, the prevalence of HCV 
co-infection is low, possibly because the number of intrave-
nous drug users among HIV-infected patients is low [36]. 
Therefore, the influence of HCV is considered minimal and it 
was associated with a low prevalence of renal insufficiency in 
Korea. In addition, tenofovir is a well-known risk factor of CKD 
and is capable of inducing renal tubular injury [8, 14]. Our 
study did not include patients taking tenofovir because tenofo-
vir has been used in South Korea only since December 2012. 
Therefore, the non-use of tenofovir may have affected our re-
sults. In addition, HIVAN is more commonly diagnosed in pa-
tients of African descent and plays an important role in ESRD 
[30]. In South Korea, there have been only three case reports of 
HIV-associated glomerulonephritis to date [37], and therefore, 
the prevalence rate is not expected to be high. This may be as-
sociated with genetic factors of HIVAN development, but addi-
tional studies including renal biopsy are needed. 
Our study identified older age and diabetes as risk factors of 
renal insufficiency in Korean HIV-infected patients. These fac-
tors are well-known risk factors associated with renal insuffi-
ciency in uninfected individuals and are also associated with 
renal insufficiency among HIV-infected patients [15, 25, 30, 
37]. In our findings, HTN and CVD were not associated with 
renal insufficiency. This may be due to the fact that the majori-
ty of patients with these conditions also had diabetes or due to 
a lack of power. In addition, a traditional CKD risk factor, BMI, 
was not significant in this study [38].
Exposure to indinavir was a significant risk factor with renal 
insufficiency in our study. Traditionally, PIs are regarded as a 
major risk factor for renal dysfunction in HIV-infected pa-
tients. PIs including indinavir have been associated with crys-
talluria, nephrolithiasis, acute or chronic interstitial nephritis, 
and renal insufficiency in previous studies [13, 14, 39]. Espe-
cially, in patients with HTN, PI use was a significant risk factor 
of renal insufficiency in this study. Therefore, in hypertensive 
HIV-infected patients, indinavir should be used with caution. 
There was no statistically significant difference in ART dura-
tion, but it was estimated that the longer ART duration of the 
renal insufficiency group might have affected renal function. 
However, research for a longer period of time may show 
meaningful results.
In this study, we found that the prevalence of renal insuffi-
ciency was high in patients who did not disclose their sexual 
behavior or did not know the route of transmission at the ini-
tial diagnosis of HIV infection. This is probably an indicator of 
the patient’s adherence and self-management status. There-
fore, patients with non-adherence may need closer monitoring 
for decreased renal function. However, because the number of 
patients in the renal insufficiency group was small in this 
study, it is possible that the effect of this factor is overestimated 
and will require additional research.
A high HIV RNA load and low CD4 cell count are also specif-
ic risks for renal insufficiency in HIV-infected patients [16, 25, 
33, 40], but these factors did not show significance in this 
study. Both groups in this study showed a low HIV RNA load 
and high CD4 cell count. Considering that these were baseline 
values at the time of study enrollment, most of the participat-
ing patients in the study had a good infection control status. 
Because all of the patients were receiving ART, these laborato-
ry results did not reflect patient risk.
Our study has several limitations. First, because of the 
cross-sectional design of this study, we could not adequately 
assess the development and persistence of the decreased 
eGFR of <60 mL/min/1.73 m2. In addition, it was not possible 
to confirm whether the renal insufficiency occurred before or 
after exposure to ART. Second, we lacked data on proteinuria 
and albuminuria, which are significant indicators of renal dys-
function in HIV patients. In addition, the prevalence of renal 
insufficiency in this study could be underestimated because 
proteinuria was not included in the definition of renal insuffi-
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ciency. Third, we used only the MDRD equation for eGFR; if 
results using the Cockcroft-Gault formula or CKD-EPI (Epide-
miology Collaboration) equation were compared, the data 
would be more meaningful. Fourth, since our patients were 
predominantly Korean men who received care in a tertiary 
hospital, our results may not be generalized to female patients, 
patients without access to healthcare, or other racial groups 
not represented in this cohort. Fifth, a large proportion of the 
patients who initially enrolled were excluded due to lack of 
data. Eventually, only 37.3% of the patients were analyzed, and 
the prevalence of renal insufficiency differed from that in all 
enrolled patients (4.04% vs. 5.3%). Therefore, the results of this 
study may not be generalizable to all Korean HIV patients.
In Korea, the prevalence rate of HIV-infected individuals is still 
low, but the cumulative number with the aging of patients is in-
creasing. In this large cohort study, the prevalence of renal insuf-
ficiency in HIV-infected patients in Korea was relatively similar 
to that in China, North America, and Europe, although the cu-
mulative prevalence rate significantly increased, indicating that 
continuous monitoring and further research are required.
In conclusion, older age, DM, taking indinavir, and unknown 
transmission route (considered to reflect adherence) were in-
dependent risk factors of renal insufficiency. In the presence of 
HTN in HIV-infected patients, the risk of renal insufficiency 
was especially higher in patients with DM and in those taking 
indinavir. In addition, the risk of renal insufficiency is not clear 
for HTN itself, but it is interpreted that the risk increases when 
other factors are also present together. Therefore, we need 
careful examination and follow-up with respect to renal func-
tion when the above factors are present in HIV-infected pa-
tients. Furthermore, we also need closer monitoring of hyper-
tensive HIV-infected patients who have DM or are taking 
indinavir. In addition, further studies of the incidence and risk 
factors of renal insufficiency during HIV infection using fol-
low-up cohort data are needed.
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